William Blair analyst Andy Hsieh has maintained their bullish stance on CRDF stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andy Hsieh has given his Buy rating due to a combination of factors surrounding Cardiff Oncology’s promising developments. The company has recently completed enrollment for its Phase II CRDF-004 study of onvansertib, targeting RAS mutation-positive metastatic colorectal cancer (mCRC). This progress is seen as a strategic move that could potentially transform treatment paradigms for this type of cancer.
Hsieh believes that Cardiff Oncology is at a pivotal moment, as the de-risking of onvansertib makes it a compelling investment opportunity. The drug’s potential to extend its application beyond colorectal cancer to other types such as pancreatic, small-cell lung, and breast cancers, further supports this optimistic outlook. These factors contribute to Cardiff Oncology being one of the top ideas in their coverage universe, reinforcing the Buy rating.